Abstract
Sensory nerves are abundant in lymphoid organs and rapidly release the neuropeptide calcitonin gene-related peptide (CGRP) in response to injury or infection. CGRP directly acts on macrophages and dendritic cells and inhibits the capacity of these cells to produce inflammatory cytokines and to present antigens to T cells. Effector mechanisms, by which CGRP acts on innate immune cells, include upregulation of IL-10, IL-10-independent induction of the inducible cAMP early repressor (ICER) and inhibition of NF-κB activity. Engagement of the CGRP receptor, which is composed of receptor activity modifying protein-1 (RAMP1) and calcitonin receptor-like receptor (CLR), increases cellular cAMP levels leading to the activation of protein kinase A (PKA). PKA appears crucial for mediating the antiinflammatory effects of CGRP. Available evidence therefore indicates that CGRP acts as a negative regulator of innate immune responses and contributes to limiting tissue damage in inflammatory disorders. In sepsis caused by mixed-bacterial infection, however, antiinflammatory activities of CGRP may exaggerate leading to immunosuppression and impaired host defense.
Keywords: CGRP. Innate immunity, ICER, IL-10, NF-κB, RAMP1, Sepsis, Immunosuppression.
Current Protein & Peptide Science
Title:Antiinflammatory Activities of CGRP Modulating Innate Immune Responses in Health and Disease
Volume: 14 Issue: 4
Author(s): Bernhard Holzmann
Affiliation:
Keywords: CGRP. Innate immunity, ICER, IL-10, NF-κB, RAMP1, Sepsis, Immunosuppression.
Abstract: Sensory nerves are abundant in lymphoid organs and rapidly release the neuropeptide calcitonin gene-related peptide (CGRP) in response to injury or infection. CGRP directly acts on macrophages and dendritic cells and inhibits the capacity of these cells to produce inflammatory cytokines and to present antigens to T cells. Effector mechanisms, by which CGRP acts on innate immune cells, include upregulation of IL-10, IL-10-independent induction of the inducible cAMP early repressor (ICER) and inhibition of NF-κB activity. Engagement of the CGRP receptor, which is composed of receptor activity modifying protein-1 (RAMP1) and calcitonin receptor-like receptor (CLR), increases cellular cAMP levels leading to the activation of protein kinase A (PKA). PKA appears crucial for mediating the antiinflammatory effects of CGRP. Available evidence therefore indicates that CGRP acts as a negative regulator of innate immune responses and contributes to limiting tissue damage in inflammatory disorders. In sepsis caused by mixed-bacterial infection, however, antiinflammatory activities of CGRP may exaggerate leading to immunosuppression and impaired host defense.
Export Options
About this article
Cite this article as:
Holzmann Bernhard, Antiinflammatory Activities of CGRP Modulating Innate Immune Responses in Health and Disease, Current Protein & Peptide Science 2013; 14 (4) . https://dx.doi.org/10.2174/13892037113149990046
DOI https://dx.doi.org/10.2174/13892037113149990046 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets BAFFling Autoimmune Disorders and Helicobacter pylori Disease: The Interplay between BAFF and the Th17 Response
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Overactive Bladder Symptoms in Patients with Fibromyalgia: A Systematic Case-Controlled Study
Reviews on Recent Clinical Trials Thymulin: An Emerging Anti-Inflammatory Molecule
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents JAK Inhibitors: Pharmacology and Clinical Activity in Chronic Myeloprolipherative Neoplasms
Current Medicinal Chemistry The TGF-β 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease
Inflammation & Allergy - Drug Targets (Discontinued) Cell Surface Markers on Adipose-Derived Stem Cells: A Systematic Review
Current Stem Cell Research & Therapy Tolerance in the Absence of Autoantigen
Endocrine, Metabolic & Immune Disorders - Drug Targets Autoimmunity and Apoptosis - Therapeutic Implications
Current Medicinal Chemistry Molecular Imaging of Stem Cell Transplantation for Neurodegenerative Diseases
Current Pharmaceutical Design Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Solid Phase Synthesis of a Glycopeptide Analogue Using the Acid Sensitive 4-Methoxybenzhydryl Bromide Resin
Protein & Peptide Letters Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders Inflammatory Events Following Subarachnoid Hemorrhage (SAH)
Current Neuropharmacology Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson’s Disease
Current Aging Science Subject Index To Volume-3
Letters in Drug Design & Discovery